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“Extracellular vesicles” (EVs) is a term gathering biological particles released from cells
that act as messengers for cell-to-cell communication. Like cells, EVs have a membrane
with a lipid bilayer, but unlike these latter, they have no nucleus and consequently cannot
replicate. Several EV subtypes (e.g., exosomes, microvesicles) are described in the
literature. However, the remaining lack of consensus on their specific markers prevents
sometimes the full knowledge of their biogenesis pathway, causing the authors to focus
on their biological effects and not their origins. EV signals depend on their cargo, which
can be naturally sourced or altered (e.g., cell engineering). The ability for regeneration
of adult articular cartilage is limited because this avascular tissue is partly made of
chondrocytes with a poor proliferation rate and migration capacity. Mesenchymal stem
cells (MSCs) had been extensively used in numerous in vitro and preclinical animal
models for cartilage regeneration, and it has been demonstrated that their therapeutic
effects are due to paracrine mechanisms involving EVs. Hence, using MSC-derived
EVs as cell-free therapy tools has become a new therapeutic approach to improve
regenerative medicine. EV-based therapy seems to show similar cartilage regenerative
potential compared with stem cell transplantation without the associated hindrances
(e.g., chromosomal aberrations, immunogenicity). The aim of this short review is to take
stock of occurring EV-based treatments for cartilage regeneration according to their
healing effects. The article focuses on cartilage regeneration through various sources
used to isolate EVs (mature or stem cells among others) and beneficial effects depending
on cargos produced from natural or tuned EVs.
Keywords: extracellular vesicles, cell-to-cell communication, stem cells, regenerative medicine, cartilage
regeneration, cell-free therapy
INTRODUCTION
With an aging population, musculoskeletal diseases remain a worldwide challenge, both economical
and therapeutic, for public health (Woolf and Pfleger, 2003; Sanchez-Adams et al., 2014; Hunter
and Bierma-Zeinstra, 2019). Among these diseases, those including articular cartilage degeneration
are very deleterious by contributing to the societal burden through disability and morbidity
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(Woolf and Pfleger, 2003; Hunter and Bierma-Zeinstra, 2019;
Komarraju et al., 2020). Cicuttini et al. (2005) examined
a population of healthy, middle-aged subjects. The authors
demonstrated that individuals with cartilage defects are affected
by a loss of articular cartilage compared with their initial
cartilage volume. This loss of cartilage represents a 2.5%
annual rate of loss in terms of cartilage volume. However, a
pathological early degeneration of articular cartilage can ensue
following osteoarthritis (OA), trauma, or other causes (infections,
hereditary conditions, etc.) (Komarraju et al., 2020). OA is
estimated to be the most common affliction triggering cartilage
degeneration by affecting more than 300 million patients all
around the world and more than 40% of the elderly older than
70 years (Hunter and Bierma-Zeinstra, 2019; Magnusson et al.,
2019; Kolasinski et al., 2020). The mechanisms causing OA are
still not fully understood, and the global therapeutic strategy is to
maintain the patient quality of life mainly by treating symptoms
(i.e., the consequences of cartilage degeneration) (Hunter and
Bierma-Zeinstra, 2019; Hsu and Siwiec, 2020; Kolasinski et al.,
2020; Oliveira Silva et al., 2020).
Articular cartilage is a hyaline cartilage covering the surface of
bones in diarthrodial joints. This specialized connective tissue is
aneuronal and avascular, meaning it does not have its own blood
supply. Therefore, its nutrition depends on synovium through the
imbibition from synovial fluid or subchondral bone, which blood
supply is brought to cartilage bounds (Oliveira Silva et al., 2020).
The main cell type constituting cartilage is called chondrocyte.
Chondrocytes are surrounded by an extracellular matrix (ECM)
they synthetize. Articular cartilage viscoelastic properties provide
wear-resistant surfaces to the joint by improving the distribution
of mechanical loads and moderating the friction between its
surfaces (Sanchez-Adams et al., 2014; Lindahl, 2015; Bianchi
et al., 2020; Masson and Krawetz, 2020). When injured or
degenerating, articular cartilage is not able to restore its original
organization because it has a very weak regenerative capacity.
The lost hyaline cartilage is replaced by fibrocartilage, but
this reparative process is mechanically inadequate with a new
cartilage lacking inherent functionality (Goldring et al., 2017;
Lepage et al., 2019; Masson and Krawetz, 2020).
OA is a disease related to cartilage degradation, osteophyte
formation, and subchondral bone alteration. It leads gradually
to a joint destruction, which generates severe impairment
of mobility for the patient (Lindahl, 2015; Hsu and Siwiec,
2020). The management of OA patients mostly starts with
non-surgical treatments that are replaced by surgical ones if
losing their efficacy. Usually, pain management is prioritized
over other treatments for early stages OA, whereas invasive
surgery is preferred for late stages (Hsu and Siwiec, 2020;
Yu and Hunter, 2020). There is still no pharmacological
treatment that would be able to repair or regenerate cartilage
(Chevalier et al., 2013). Cartilage repair can be enhanced
by surgery as described hereinafter. Conventional surgical
approaches include methods such as subchondral bone
microfracture, soft tissue transplantation with an autograft of
periosteum/perichondrium, osteochondral allograft/autograft
transplantation, and autologous chondrocyte implantation
(Bakhshayesh et al., 2020). When effective, these methods
often lead to the production of fibrocartilage instead of hyaline
cartilage. It is important to integrate that repair is different from
regeneration. Repair means healing joint through fibrocartilage
synthesis, resulting in a tissue with poorer functional quality
that is not mechanically equivalent to native hyaline cartilage
and cannot restore full original function. Besides, end-stage
OA leads to invasive surgery with total joint replacement
by limited life prostheses (Chard et al., 2005; Lindahl, 2015;
Kolasinski et al., 2020).
Regenerative medicine strategies have been initiated as a new
opportunity to treat cartilage defects and bring regeneration
along. Numerous tissue engineering approaches have been
developed by using biomaterials as ECM derivatives or
mesenchymal stem cells (MSCs) as chondrogenic precursors
to alleviate the lack of accessibility for primary chondrocytes
(Bakhshayesh et al., 2020; Tsiapalis and O’Driscoll, 2020).
Because of their promising results in vitro or on animal models,
these approaches are currently investigated to be transferred to
clinic practice (Borić et al., 2019; Kim et al., 2020; Kyriakidis
et al., 2020; Lehoczky et al., 2020; Mendes et al., 2020). Cell
therapy approaches involving patients are also encouraging, and
many clinical trials are ongoing. Larger sample sizes and long-
term follow-ups would be necessary for a validation in the
clinics. In addition, the proof of effectiveness for intra-articular
cell injection remains limited in terms of repair as much as
regeneration (Ha et al., 2019; Monckeberg et al., 2019; Lee et al.,
2019; Zhao et al., 2019).
Other regenerative medicine strategies involved cell-free
therapies by delivering exogenous active biomolecules (growth
factors, drugs, etc.) as therapeutic agents directly through intra-
articular injection. The flaws of this route are that most mediators
have a short half-life and are promptly removed from the joint
space and that mediators cannot reach chondrocytes suitably
because these cells are embedded into a thick avascular ECM (Yan
et al., 2019; Eckstein et al., 2020). The first flaw can be moderated
by encapsulating the mediator in an appropriate scaffold to
ensure a gradual diffusion inside the joint and a more long-
lasting effect, but the ECM penetration to get to chondrocytes still
remains challenging (Szychlinska et al., 2018).
The cells, among which MSCs are the most solicited, used in
tissue engineering or cell therapy are supposed to have intrinsic
capabilities to mediate tissue repair. For example, numerous
studies have now demonstrated that MSC healing effect is a
paracrine effect due to cell secretome (Julianto and Rindastuti,
2016; Khatab et al., 2018; Chen et al., 2019b; Niada et al.,
2019; Mancuso et al., 2019; Brennan et al., 2020; Parate et al.,
2020; Ragni et al., 2020b; Kadir et al., 2021). The secretome
includes all cell secretions, i.e., soluble mediators (growth factors,
cytokines, etc.) (Maumus et al., 2017) and also very unique
entities called extracellular vesicles (EVs) (Dostert et al., 2017;
Tsiapalis and O’Driscoll, 2020).
Since the first decade of the twenty-first century, literature
about EVs has been growing exponentially. But in parallel, a
lack of accuracy for certain publications was noticed by experts
in the field. A new scientific community in need of dogma
developed around EV research leaders resulting in the foundation
of the International Society for Extracellular Vesicles (ISEV) in
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2012 (Witwer and Théry, 2019). EVs are commonly described as
membranous entities released by every cell type into extracellular
space. They are not able to replicate and are involved in cell-to-
cell communication. Most publications depict EVs as particles
enriched with components from the releasing cell and bordered
by a lipid bilayer comparable to the plasma membrane (Yáñez-
Mó et al., 2015). Many subtypes of cell-released structures
are encompassed in the term “EV” [e.g., small/medium/large
vesicles, exosomes, ectosomes, oncosomes, microvesicles (MVs),
microparticles, apoptotic bodies (ABs), matrix vesicles, etc.].
Consequently, the whole EVs constitute hard-to-characterize
heterogeneous populations. The worldwide harmonization on
“how to term” the various EV subtypes has still not been set,
and their designation could depend on the size, biogenesis,
specific markers, location or origin (ECM, cell/tissue, tumor, etc.),
and/or conditioning (identified culture conditions). This lack of
consensus can sometimes make the designation of EV subtypes
ambiguous (Théry et al., 2018; Witwer and Théry, 2019).
Three categories of EVs are frequently found in publications
and are described according to biogenesis. ABs are large
EVs (±1–5 µm) released after dismantling of apoptotic
cells and made of subcellular fragments. MVs, also termed
ectosomes or microparticles, are medium/large EVs (±100 nm
to 1 µm) materialized from the budding of the plasma
membrane. Exosomes are small EVs (±30–150 nm depending
on the authors) derived from endocytic pathway (Dostert
et al., 2017; Witwer and Théry, 2019; Cocozza et al., 2020;
Tsiapalis and O’Driscoll, 2020).
In 2014, ISEV set up guidelines called minimal information
for studies of EVs (MISEV), which were updated in 2018.
MISEV were a necessary step to support scientists interested
in this complex and still evolving field and to clarify/prevent
the confusion about EV designation. MISEV2018 define “EV”
as a generic term. The authors are free to choose the required
approaches to characterize EV subtypes. However, if they cannot
match the guidelines to validate EV identity, they are requested
to use the term extracellular particle or to find their own
term after setting a clear definition (Théry et al., 2018). For
example, extracellular mitochondria alone or encapsulated in
vesicles constitute a noticeable subset of EVs (Puhm et al.,
2019; Al Amir Dache et al., 2020). Likewise, Yefimova et al.
(2020), have recently designated a new kind of EVs found in
seminal plasma called myelinosome. Myelinosomes are secretory
organelles entirely released by Sertoli cells through a process
close to endocytic pathway. These newly discovered EVs have a
multilamellar demarcation very different from the lipid bilayer
typically encountered in EVs (Yefimova et al., 2020).
EVs have many interesting assets that could improve cartilage
defects. They have the innate capacity to target difficult-to-
reach places by crossing the blood–brain barrier or ECM.
Their membranous structure allows protecting their cargo
from the environment. According to their sources, they have
immunomodulatory properties and are biocompatible (Tsiapalis
and O’Driscoll, 2020). All these benefits offer new insights to use
EVs as regenerative medicine tools to heal cartilage.
This mini review summarizes current EV-based treatments to
improve cartilage degeneration by focusing on various sources
to produce EVs and the positive effects of the therapeutic cargos
from natural or modified EVs.
BIOLOGICAL SOURCE-DERIVED EVs
FOR CARTILAGE HEALING
EVs participate in the modulation of numerous cell regulatory
processes (e.g., proliferation, differentiation, or inflammation),
making these membranous entities perfect stakeholders for tissue
regeneration according to their various sources (Dostert et al.,
2017; Tsiapalis and O’Driscoll, 2020). EVs are secreted by diverse
cell types and found in solid tissues (e.g., ECM) or in body
fluids (blood, saliva, urine, milk, etc.). They can be isolated from
these biological samples, but determining their exact cell origin
is not always possible because of their heterogeneity. According
to the use of EVs, particularly for therapeutic purpose, their
availability in sufficient quantity must be demonstrated to prevent
precious sample scarcity and to ensure the results obtained
from their exploitation. Despite the restrictions linked to good
manufacturing/clinical practice (GMP/GCP), cell culture is also a
reasonable answer to overcome the lack of biological sources and
to standardize an in vitro EV production from a well-defined cell
type. It allows EV isolation from cell-conditioned medium (Théry
et al., 2006, 2018; Grant et al., 2011; Chen et al., 2013; Wolf et al.,
2015; Iwai et al., 2016; Palamà et al., 2020; Ragni et al., 2020b).
Blood products, such as serum- or plasma-based whole-
blood derivatives, have a good tolerance and can reduce pain
and inflammation. Intra-articular injection of blood products
over other intra-articular treatments has been investigated
and improves pain scales in knee OA. The benefits become
statistically and clinically significant starting from 6 months
and increase up to 12-month follow-up (Filardo et al., 2020).
Whole blood non-invasively drawn from patients allows a direct
conditioning to obtain autologous blood-derived products with
a higher tolerance (Gato-Calvo et al., 2019). Among cell-free
strategies to regenerate cartilage, EVs from autologous blood
products have a stronger effect in OA chondrocytes than full
blood products by influencing cartilage ECM metabolism and
inflammation. Acute OA could be improved by the positive anti-
inflammatory effect of citrate-anticoagulated platelet-rich plasma
EVs. Chronic OA could benefit the chondrogenesis elicited by
hyperacute serum EVs. These promising in vitro results have to
be tested in vivo to demonstrate cartilage regeneration (Otahal
et al., 2020; Figures 1A,C).
Current regenerative strategies for cartilage regeneration
rely on the use of MSCs. These cells are multipotent with
a chondrogenic potential. They also have self-renewal and
immunomodulatory properties (Dostert et al., 2017; Tsiapalis and
O’Driscoll, 2020). However, using growth factors to differentiate
MSCs toward an articular phenotype remains difficult and
can lead to hypertrophy associated with unwanted ossification
(Deng et al., 2019). Lately, primary articular chondrocytes
harvested from patients who underwent polydactyly surgery
were used to produce EVs. The aim was to use chondrocyte-
derived EVs (C-EVs) instead of growth factors to mediate
MSC differentiation into chondrocytes. Human umbilical
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FIGURE 1 | Therapeutic effects of natural EV-based therapy for cartilage healing. (A) Various cell sources for generating non-modified EVs. (B) Example of
therapeutic cargos for natural EVs conveying proteins (TGFBI), nucleic acids (lnc KLF3-AS1, miR-100-5p), or lipids (SP1). (C) EV therapeutic effects on cartilage
injury or OA. ECM, extracellular matrix; EV, extracellular vesicle; iPSC, induced pluripotent stem cell; iMSC, induced pluripotent stem cell-derived mesenchymal stem
cell; lncRNA, long non-coding RNA; miR, microRNA; MSC, mesenchymal stem cell; OA, osteoarthritis; S1P, sphingosine-1-phosphate; TGFBI, transforming growth
factor β–induced protein.
cord–derived MSCs (UCMSCs) were treated with C-EVs.
In vitro, C-EVs promoted chondrogenic differentiation of MSCs
and decreased fibrotic and hypertrophic markers. In vivo, MSCs
conditioned by C-EVs were successfully used to repair knee
cartilage defect in a rabbit model. This approach needs further
developments to be tested for human therapeutic purpose. Its
main flaws reside in the accessibility of mature chondrocytes
and their tolerance in an allogeneic context (Ma et al., 2020;
Figures 1A,C).
MSCs have a unique capacity to build a regenerative
microenvironment, which is considered to promote
chondrogenic differentiation in the case of cartilage injury
through soluble mediators and EVs. In vitro and in vivo studies
have demonstrated the immunomodulatory, chondroprotective,
and regenerative effects of MSC-derived EVs (MSC-EVs), which
is equivalent or superior to MSCs alone. Harvesting human
adult MSCs (e.g., bone marrow, adipose tissue, or dental pulp)
often requires invasive procedures, and these cells are not
systematically available, particularly in sufficient amount for
cell therapy or tissue engineering. Consequently, adult MSCs
need to be expanded in vitro, which can lead to chromosomal
aberrations. EV-based therapy is an answer to alleviate the
previous hindrances and potential cell immunogenicity.
The stemness of adult MSCs decreases with the increase of
the donor age. Adult MSCs have limited self-renewal and
immunomodulation properties compared with perinatal MSCs
(e.g., cord blood or umbilical cord connective tissue, also known
as Wharton jelly) or MSCs derived from embryonic stem
cells. Perinatal MSCs are easily harvested, whereas embryonic
MSCs can cause ethical issues. Induced pluripotent stem cells
(iPSCs) have limitless self-renewal and can differentiate into
MSCs to generate iPSC-derived MSCs (iMSCs). Nevertheless,
the use of iPSCs or iMSCs in clinics is questionable because
of their possible genomic instability, immunogenicity, and
tumorigenicity (Zhang et al., 2016; Dostert et al., 2017; Zhu et al.,
2017; Tsiapalis and O’Driscoll, 2020). Whether it is from an
allogeneic or an autologous origin, the best source of MSC-EVs
has not been yet highlighted. Several examples of MSC-derived
EV therapy will be illustrated in the following sections of this
article. To date, there is only one clinical trial involving EVs to
treat cartilage injury. It is based on the promising results from
Niada et al. (2019), where MSCs derived from adipose tissue of
healthy donors undergoing aesthetic or prosthetic surgery. This
observational study has been posted in January 2020, and there is
still no recruitment (National Clinical Trial no. NCT04223622)1.
One of its purposes is to validate a cell-free approach based
on the use of EVs produced by adipose tissue–derived MSCs
(ATMSCs) to improve an ex vivo OA model. Besides, one of the
possible sources of autologous ATMSCs could come from OA
patients’ infrapatellar fat pad (IFP) obtained after arthroscopy,
1https://clinicaltrials.gov
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although such cells may be compromised in their regenerative
potential as the IFP has been involved in the pathogenesis of
OA. Autologous MSCs from OA patients’ joint tissues such
as the synovium or IFP could originate from an inflammatory
environment characterized by progressive OA causing their
potential priming by proinflammatory factors. This priming does
not seem to compromise the healing aptitudes of MSCs. Instead,
Kouroupis et al. (2019) showed that primed MSCs derived from
the IFP exhibit enhanced immunomodulatory properties in vitro
and in vivo (Figures 1A,C).
THERAPEUTIC EFFECTS OF REGULAR
EVs FOR CARTILAGE HEALING
The therapeutic effects of EVs depend on the cargo they
conveyed. Indeed, tissue regeneration relies on healing factors
carried by EVs to generate a trophic microenvironment suitable
for chondrogenesis and hyaline ECM upkeep (Liu et al.,
2017; Tao et al., 2017; Jing et al., 2020; Zhao et al., 2020).
EVs can be untouched and used as therapeutic agents in
their regular or natural state after isolation from biological
samples or conditioned medium in standard cell culture
conditions (Figure 1).
The following studies highlight the molecules of interest
conveyed by therapeutic EVs that could become part of the
future strategies used for cartilage healing. Transforming growth
factor β (TGF-β) is a major regulator of cartilage homeostasis,
and the deregulation of its pathway is involved in OA.
A member of the TGF-β family, the TGF-β–induced protein
(TGF-BI), is upregulated in bone and cartilage of OA patients,
but is downregulated in human bone marrow–derived MSCs
(BMMSCs) (Ruiz et al., 2019). Recently, Ruiz et al. (2020), showed
that TGBI silencing inhibits murine BMMSCs’ chondroinductive
effect in vitro and healing effect in a collagenase-induced OA
mouse model. These positive effects are due to the presence of
TGF-BI mRNA and protein in BMMSC-derived EVs, suggesting
that TGF-BI is a new key factor released by MSCs to protect
cartilage and favor its anabolism (Ruiz et al., 2020). The long non-
coding RNA (lncRNA) KLF3-AS1 (see Ref seq NR_026804.1)
is found in human MSCs and their EVs. When used in an
in vitro OA model based on rat articular chondrocytes treated
with the proinflammatory cytokine interleukin 1β (IL-1β), EVs
carrying lncRNA KLF3-AS1 suppress IL-1β–induced apoptosis
of chondrocytes. Additionally, these EVs engender cartilage
repair and chondrocyte proliferation in a knee collagenase–
induced OA rat model (Liu et al., 2018b). EV subtypes secreted
by human BMMSCs contain a high level of sphingosine-1-
phosphate (S1P) compared with MSCs alone. This enrichment
is due to the cell enzyme sphingosine kinase 1. S1P-enriched
EVs enhance the proliferation of human chondrocytes and
inhibit IL-1β–induced apoptosis in vitro. In a rabbit model of
knee articular cartilage injury made by drilling, the injection
of these EVs into the knee capsule promotes the recovery of
the cartilage defect (Xiang et al., 2018). OA patients’ ATMSCs
derived from IFP released EVs conveying high levels of miR-100-
5p. These EVs inhibit cell apoptosis, promote ECM anabolism,
and repress ECM catabolism in an in vitro OA model made
of OA patients’ chondrocytes treated with IL-1β. Intra-articular
injections of these ATMSC-EVs in a mouse model based on knee
joint instability induced by surgery enhance articular cartilage
protection from damage and improve gait abnormality due to OA
pain and disturbance (Wu et al., 2019; Figures 1B,C).
One of the limitations to have information on EV cargos
is that numerous studies characterize EV effects and not their
content or membrane composition. Moreover, the differences
between cell type and cell donor have to be taken into account
to ensure the potential of the therapeutic message conveyed by
EVs (Ragni et al., 2019). The following examples illustrate the
positive use of natural EVs on cartilage without deciphering
their cargos. It was previously mentioned that blood product–
derived EVs beneficially influence cartilage ECM metabolism and
inflammation in vitro (Otahal et al., 2020) and that articular
C-EVs favor chondrogenic differentiation of human UCMSCs
in vitro and in vivo (Ma et al., 2020). Besides, human embryonic
MSC-derived EVs promote cartilage regeneration in an adult rat
cartilage defect model (Zhang et al., 2016). In an OA model based
on rabbit chondrocytes treated with IL-1β, EVs secreted by rabbit
BMMSCs prevent chondrocyte mitochondrial-induced apoptosis
in response to IL-1β in vitro (Qi et al., 2019). Human BMMSCs
produce chondroprotective and anti-inflammatory EVs in vitro
that prevent mice to develop collagenase-induced OA (Cosenza
et al., 2017; Vonk et al., 2018). EVs secreted by human synovial
membrane–derived MSCs (SMMSCs) and human iMSCs are able
to attenuate OA in the same animal model. However, human
iMSC-EVs show a superior therapeutic effect associated with an
improvement of chondrocyte migration and proliferation (Zhu
et al., 2017). Intra-articular injections of human iMSCs-derived
EVs also allow ECM restoration and cartilage regeneration
in a rat temporomandibular joint OA model induced by
monosodium iodoacetate (Zhang et al., 2019). In addition, EVs
secreted by human iMSCs alleviate OA in the mouse, in vitro in
chondrocytes treated with IL-1β and in vivo by limiting cartilage
destruction and matrix degradation according to Osteoarthritis
Research Society International (OARSI) scores in a model based
on knee joint instability induced by surgery (Wang et al.,
2017). Human ATMSCs derived from abdominoplasty release
EVs that decrease the inflammation caused in vitro by IL-1β
in patient-derived OA chondrocytes (Tofiño-Vian et al., 2018;
Figures 1A,C).
Furthermore, EVs can also be tuned to carry selected
mediators favoring a specific enrichment to elicit cartilage
regeneration. On the one end, engineered or primed tissues/cells
can lead to the production of enriched EVs. On the other hand,
EVs can also be loaded after their isolation.
THERAPEUTIC EFFECTS OF TUNED EVs
FOR CARTILAGE HEALING
Tuning EVs to increase their therapeutic potential require EV
drug-loading strategies. Priming or transfecting cells involved
an EV loading performed by the donor cell, which secrete EVs.
Postisolation drug loading occurs after EV secretion by the
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FIGURE 2 | Tuning methods to improve the drug loading of therapeutic EVs for cartilage healing. (A) Methods of modifications used before EV isolation to tune EVs
with (i) cell engineering by transfecting cells or (ii) cell priming by treating cells with soluble mediators added to cell culture medium. (B) Methods of modifications
used after EV isolation to tune EVs with miRNA electroporation. DC, dendritic cell; EV, extracellular vesicle; CAP, chondrocyte affinity peptide; IFN-γ, interferon γ;
lncRNA, long non-coding RNA; M2Mϕ, M2 macrophage; miR, microRNA; miRNA, microRNA; MSC, mesenchymal stem cell; TGF-β1, transforming growth factor β1.
donor cell. EV-based therapy for cartilage regeneration with
tuned EVs depends mainly on RNA loading from transfected
MSCs (Figure 2).
As previously described, lncRNA KLF3-AS1 conveyed by
MSC-EVs improves OA in vitro and in vivo by respectively,
suppressing IL-1β–induced apoptosis of chondrocytes and
eliciting cartilage repair and chondrocyte proliferation in a knee
collagenase-induced OA model (Liu et al., 2018b). The role of
lncRNAs is to act as competitive endogenous RNA (ceRNAs)
to separate microRNAs (miRNAs) from target mRNAs, and
thus restoring mRNA expression. Among miRNAs, miR-206
is known to be highly expressed in OA. When transfected
to overexpress lncRNA KLF3-AS1, MSCs release EVs with a
high load of this lncRNA. These enriched EVs used in similar
in vitro and in vivo models showed a significant improve of
IL-1β–induced chondrocyte apoptosis and cartilage injury. The
authors demonstrated that lncRNA KLF3-AS1 conveyed by
MSC-EVs acts as a ceRNA to prevent miR-206 to downregulate
G-protein-coupled receptor kinase interacting protein-1 (GIT1)
expression, which induces EV therapeutic effects. Indeed, GIT1
inhibits chondrocytes apoptosis and promotes chondrocytes
proliferation. Delivering this lncRNA by EVs into cartilage could
be a future strategy for cartilage regeneration (Liu et al., 2018a;
Figure 2Ai upper panel).
In an OA rat model based on knee joint instability induced
by surgery, human SMMSCs promote to a lesser extent the
same positive effects -as described previously- but inhibit
the synthesis of chondrocyte ECM (Tao et al., 2017). The
microRNA (miR)-140-5p is known to play a role in chondrogenic
differentiation and OA prevention (Tardif et al., 2009; Barter
et al., 2015). SMMSC-derived EVs contain this miRNA weakly.
When modified to overexpress miR-140-5p, SMMSCs secrete
EVs enriched in miR-140-5p. This packaging enhanced the
healing properties of human SMMSC-EVs by delaying the
progression of early stage OA and cartilage damage (Tao et al.,
2017). Likewise, miR-26a-5p and miR-31 promote chondrocyte
proliferation and improve OA. Respectively, human BMMSCs
and human SMMSCs overexpressing miR-26a-5p and miR-31
secrete EVs enriched in these miRNAs. These EVs alleviate
cartilage destruction, matrix degradation, and inflammation in
OA models based on knee joint instability induced by surgery,
in the rat for EVs carrying miR-26a-5p according to the authors’
subjective scores based on synovitis inflammation, synovial
thickening, and subchondral bone erosion (Jin et al., 2020) and
in the mouse for EVs carrying miR-31 according to OARSI
scores (Wang et al., 2020). EVs derived from rat BMMSCs
transfected to overexpress miR-135b favor rat chondrocyte
proliferation in vitro (Wang et al., 2018). Human BMMSCs
overexpressing miR-92a-3p, a chondrogenesis promoter and
cartilage degradation inhibitor (Mao et al., 2017), produce
EVs sustaining its properties in vitro. Human BMMSC-EVs
enriched in miR-92a-3p interfere with the progression of early-
stage OA and prevent cartilage damage in a knee collagenase–
induced OA mouse model (Mao et al., 2018). Human BMMSCs
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undergoing chondrogenic differentiation upregulate the EV
loading of specific miRNAs, like miR-320c. EVs derived from
human BMMSCs transfected to overexpress miR-320c promote
OA patients’ chondrocyte proliferation and migration and
increase human BMSC chondrogenesis (Sun et al., 2019). The
previous studies demonstrate the potential of miRNA-loaded
EVs to develop novel therapeutic strategies for cartilage healing
(Figure 2Ai upper panel).
Palamà et al., showed that human BMMSCs grown in a xeno-
free culture system produce chondroprotective EVs in vitro.
In addition, these EVs were produced in a higher amount
and inhibit the adverse effects of IL-1α-induced inflammation
in an in vitro OA model compared with cells grown in a
conventional culture system with fetal bovine serum (Palamà
et al., 2020). This demonstrates that a xeno-free environment
can prime cells and influence EV composition and consequently
EV effects. Similarly, cell priming with biochemical factors
influences EV cargos. EVs derived from rat BMMSCs primed
with TGF-β1 are enriched in miR-135b and favor rat chondrocyte
proliferation by upregulating S1P in vitro (Wang et al., 2018).
Moreover, these EVs engender cartilage repair in a rat OA model
based on knee joint instability induced by surgery. Interferon
γ (IFN-γ) is a versatile proinflammatory cytokine involved in
tissue regeneration. In vitro IFN-γ–primed human ATMSCs
secrete EVs enriched in chondroprotective and M2 (i.e., anti-
inflammatory) macrophage polarizing miRNAs (Ragni et al.,
2020b). This cargo improvement makes a suitable association to
promote cartilage regeneration (Figure 2Aii).
The delivery of EVs after intra-articular administration in
chondrocytes remains challenging as these cells are surrounded
by an avascular, dense ECM. The density of hyaline ECM is
due to proteoglycans with high negative charges entangled in
a collagen fibril network. Only solutes less than or equal to
10 nm have been shown to cross this thick barrier and penetrate
the cartilage (Bajpayee et al., 2014). Although EVs are greater
than 10 nm and have a slight negative charge that could push
them away from cartilage, the previous references showed their
healing effects on damaged cartilage whether they are regular
or tuned. However, their penetration in the hyaline ECM has
not always been tested. Recently, Liang et al. (2020), transfected
dendritic cells to produce engineered EVs that are tagged with
a chondrocyte affinity peptide (CAP) at their surface. CAP-EVs
have the same size range (40–200 nm) as EVs without CAP.
CAP-EVs target and enter selectively chondrocytes in vitro and
in vivo. They can more efficiently and deeply penetrate healthy rat
cartilage than non-tagged EVs that mainly reside in the surface
layer. After their isolation, CAP-EVs and non-tagged EVs were
loaded with miR-140 mimic by electroporation. Loaded CAP-
EVs were able to improve an in vitro OA model based on human
articular chondrocytes treated with IL-1β by a targeted delivery of
miR-140. Intra-articular injection of EVs was made in an OA rat
model based on knee joint instability induced by surgery. CAP-
EVs remained preferentially into cartilage with minimal diffusion
compared with non-tagged EVs. Loaded CAP-EVs delivered
miR-140 to deep cartilage areas and prevent cartilage degradation
and OA progression (Liang et al., 2020; Figure 2Ai lower panel,
Figure 2B).
EVs can penetrate deep down into tissue, and their faintly
negative net charge allows long circulation in the body.
Moreover, they are able to escape immune cells by avoiding
clearance or degradation (Malhotra et al., 2016; Vader et al.,
2016). These assets made them ideal biocompatible carriers to
convey molecules of interest for cartilage healing. Whatever EV
enrichment, all of these molecules have not yet been discovered,
and there is still an in-depth screening ongoing to bring them
up to light by the scientific community (Endisha et al., 2018; Sun
et al., 2019; Ragni et al., 2020a).
DISCUSSION
Although a lack of consensus concerning EV isolation methods
and EV characterization/designation remains, EV therapeutic
potential cannot be denied to improve cartilage injury as
shown in the preclinical studies presented in this article. Cell-
free therapy based on EVs appears to demonstrate similar
or sometimes even better regenerative properties of cartilage
compared with cell therapy. For example, phosphate-buffered
saline (PBS), EVs derived from human BMMSCs, or human
BMMSCs were injected in the knee capsule in a rabbit model
of knee articular cartilage injury performed by drilling. The
control group treated with PBS exhibited defect filling with
adipose and fibrotic cells but without ECM, suggesting a poor
cartilage repair. The EV-treated group or the MSC-treated group
displayed contrasting results, with defects progressively filled
by a hyaline cartilage–like tissue. There was no significant
difference between the EV-treated and MSC-treated groups,
indicating that EVs are as efficient as MSCs to promote the
recovery of cartilage defects (Xiang et al., 2018). Similarly,
intra-articular injection of human BMMSC full secretome
(containing EVs), equally to injection of human BMMSCs,
was shown to reduce pain and have protective effects on
the development of cartilage damage in a knee collagenase–
induced OA mouse model (Khatab et al., 2018). Cosenza et al.
(2017) reported the superiority of human BMMSC-EVs over
human BMMSCs to protect the joint from OA in the same
in vivo preclinical model. Moreover, EVs are easier to handle
and display minor regulatory concerns compared with cells,
mainly because they are less immunogenic, and because they
have no nucleus, they do not replicate. To translate EV-based
therapy into clinics, several hurdles would have to be overcome
to guarantee the procurement of safe therapy products and
prevent side effects, such as EV cell sources/donor related to
potential immunogenicity and EV dose and route related to
pharmacokinetics, pharmacodynamics, and toxicity (Théry et al.,
2018; Tieu et al., 2020).
Alongside the GMP/GCP, the future of patients’ cartilage
regeneration appears to have a great potential within cell-free
therapies based on EVs. EV aptitude to cross ECM allows them
to reach and heal cartilage. However, to penetrate the cartilage,
EVs seemed to need a special tag allowing to cross the hyaline
ECM. While tuned EVs can be enhanced to carry an established
tag (Liang et al., 2020), regular EV healing cartilage could be
enriched and carry inherently those kinds of tags such as S1P
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(Xiang et al., 2018). The selective mechanisms to favor EVs and
ECM interaction could rely on a chemotactic response (Headland
et al., 2015). According to the disease state of OA and to the depth
of the defects, EVs could also have an easier access to exposed
chondrocytes without being hindered by the hyaline ECM, which
is removed from cartilage by erosion.
EVs are used in their natural state or tuned to be drug-
loaded in order to be enriched with cartilage regenerative
RNAs (e.g., miRNAs or lncRNAs). The tuning can also apply
to EV membrane to improve chondrocyte targeting (e.g.,
surface modification with CAP). To date, these modifications
are the only existing for cartilage, despite a broad range of
possibilities that would probably inspire forthcoming research
(Liao et al., 2019). Strategies using cotherapy by tuning EVs
with drug encapsulation can also be considered to boost cartilage
regeneration. For example, loading EVs with pharmacological
agents such as glucosamine, chondroitin sulfate, or non-steroidal
anti-inflammatory drugs could improve ECM degradation and
reduce pain and cartilage degeneration (Artuzi et al., 2020; Sun
et al., 2020). Although liposomes can be used as synthetic vesicles
to convey drugs to cells, it has been shown that they could be
silenced through phagocytosis by monocytes and macrophages.
Consequently, they require surface adjustments to obtain smart
targeting abilities. EVs carry specific membrane proteins that
protect them from phagocytosis and facilitate their delivery
(Kamerkar et al., 2017). A strategy for cotherapy could also be
to engineer “smarter” delivery systems by creating hybrid EV-
liposome carriers with membrane fusion (Elkhoury et al., 2020).
Apart from cell-free therapy, EVs can also be used for cartilage
tissue engineering strategies by being associated with implantable
engineered constructs (Malda et al., 2016; Szychlinska et al.,
2018). After being implanted subcutaneously in nude mice,
constructs made of rabbit cartilage progenitor cells and alginate
have developed into ectopic cartilage once injected with rabbit
C-EVs (Chen et al., 2018). An acellular tissue patch made of
hydrogel glue and human iMSC-EVs was tested in a rabbit model
of patellar groove defect. The hydrogel glue could retain and
then release EVs sustainably. The patch was easily integrated
to cartilage ECM and improved the articular cartilage injury
through cell deposition (Liu et al., 2017). The same animal model
was used to test a three-dimensional (3D) construct printed
with a bioink made of cartilage ECM, gelatin methacrylate,
and BMMSC-EVs. The 3D construct stimulated chondrocyte
migration and M2 macrophage polarization and also elicited
cartilage regeneration (Chen et al., 2019a). Like cell-free therapies
based on EVs, few EV-based tissue engineering strategies have
been investigated in the field of cartilage regeneration, and the
course to new discoveries remains.
All the presented preclinical studies show that EVs embody a
great hope to become part of the next-generation treatments in
regenerative medicine for articular cartilage regeneration.
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